Virtual ISPOR Europe 2021

Share on:

Tuesday, November 30 - Friday, December 3, 2021

Emerging Frontiers and Opportunities: Special Populations and Technologies

RTI Health Solutions is proud to be a virtual exhibitor this year. Our researchers will be presenting research and moderating several sessions for Virtual ISPOR Europe 2021. Take a look.

View our Scientific Contributions

Get to Know our Team

Schedule a Meeting with our Experts

Conference Schedule

Times within the program below are in Central European Time (CET) (UTC-5).

Issues Panel | Conference registrants will continue to have access to session recordings, posters, and exhibits until 2 January 2022

111IP

30 Nov | 16:00 - 17:00

Expanding the notion of value of new health technologies: should preventive interventions be differently considered than therapeutics? Moderator: Josephine Mauskopf, PhD, Live Q&A

On-Demand Podium Sessions - Viewable from 22 November 2021 to 2 January 2022.

Moderator: Sorrel Wolowacz, PhD

Development and Measurement of Health Utilities.

Moderator: Lynda Doward, MRes

Is Social Media Information Useful to Understand Patient Experiences and the Burden of Disease?

Moderator: Thor-Henrik Brodtkorb, PhD

Issues with Health Technology Assessment of Specialised Technologies.

Moderator: Carla DeMuro, MS

Two Years of COVID-19: What Has Been the Global Impact on HRQoL and Clinical Outcomes?

Virtual Poster Discussion Session 1 – Tuesday, 30 November

POSA311

Methodological & Statistical Research: Oncology

Surrogate outcomes for overall survival in pretreated non-small cell lung cancer: expanding the prediction range. Jen MH, Sonksen M, Kiiskinen U, Wolowacz S, Vickers AD, Hawe E.

POSA362

Patient-Centered Research: Drugs | Gastrointestinal Disorders

Symptom assessment in adolescents and adults with celiac disease. Martin SA, Meckley LM, Harris NI, Chen KS, Leffler DA.

Virtual Poster Discussion Session 2 – Wednesday, 1 December

POSB70

Economic Evaluation: Cardiovascular Disorders

Systematic literature review of cost and data sources for economic evaluations in hypercholesterolaemia and mixed dyslipidaemia from a UK perspective. Spentzouris G, Bilitou A, Manga N, McCrink L, Pearson I, Mitchell S, Moss E, Rothwell B.

POSB145

Economic Evaluation: Drugs | Systemic Disorders/Conditions

Budget impact of pegcetacoplan, a complement c3 inhibitor, for the treatment of paroxysmal nocturnal hemoglobinuria in US adults. Anderson S, Talbird SE, Fishman J, Mody-Patel N, Sarda SP.

POSB298

Medical Technologies: No Specific Disease

DRG-based reimbursement and payment modalities for innovative remote patient monitoring technologies. D'Souza V, Njue A, Heyes A.

POSB142

Economic Evaluation: Musculoskeletal Disorders | Rare and Orphan Diseases

Targeted literature review of the burden of illness in late-stage Duchenne Muscular Dystrophy (DMD). Lunan M, Hartley L, Pearson I, Doyle S.

Virtual Poster Discussion Session 3 – Thursday, 2 December

POSC43

Economic Evaluation: Rare and Orphan Diseases

POSC105

Economic Evaluation: Multiple Diseases | Pediatrics | Vaccines

Economic evaluation of the pediatric immunization program in Belgium. Carrico J, Mellott C, Talbird S, Abreu A, Merckx B, Vanderhaute J, Benchabane D, Dauby N, Ethgen O, Lepage P, Luyten J, Raes M, Simoens S, Van Ranst M, Bencina G, Nyaku MK.

ISPOR Training Course | This course is not included in Virtual ISPOR Europe, so it has a separate registration. Taught by seasoned HEOR experts from RTI Health Solutions.

6-9 December 2021

ISPOR Budget Impact Analysis II Course

Budget Impact Analysis II covers the concrete application of the 6-step approach for developing budget impact analyses and provides hands-on learning with two different budget impact models programmed in Excel. Course faculty: Stephanie Earnshaw, PhD, Anita Brogan, PhD, Thor-Henrik Brodtkorb, PhD, and Ashley Davis, PhD.

Virtual ISPOR Europe 2021

Emerging Frontiers and Opportunities: Special Populations and Technologies

Conference Schedule

Conference Participants